0 of 6 Questions completed
Questions:
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading…
You must sign in or sign up to start the quiz.
You must first complete the following:
0 of 6 Questions answered correctly
Your time:
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
You must score 0% to continue. Please click the link below to re-take the quiz
1. How confident are you in the management of patients with AD in your practice?
2. How would you classify the severity of AD in a patient with perceptible erythema, papulation, and lichenification with mild oozing?
3. In addition to basic management comprising skin care and trigger avoidance, which of the following treatments would you prescribe for a patient with marked erythema, induration, and lichenification affecting 40% of the body, including the face and hands?
4. Approximately what proportion of pediatric patients with moderate-to-severe AD has been shown to achieve ≥75% improvement in lesion extent and severity when dupilumab is combined with TCS therapy?
5. How does the rate of ISGA (Investigator’s Static Global Assessment) success in crisaborole-treated infants 3 months to <24 months compare with that observed in previous studies of similarly treated patients ≥2 years of age?
6. Casey is a 7-year-old with a 5-year history of mild-to-moderate AD. His parents report that, despite diligent treatment with a TCI, he frequently wakes up during the night due to itching, and that his behavior and academic performance at school are increasingly being affected. According to current best practice recommendations, what is the most appropriate next step for Casey?